Search results: (10000)
News Meta-analysis of Efficacy and Safety of Antidiabetics in Treating Gestational DM
What efficacy and safety do insulin, metformin, or the sulfonylurea derivative glibenclamide (glyburide) offer in lowering glucose levels in women with gestational diabetes? The authors of a meta-analysis of randomized controlled trials used a probabilistic model – a Bayesian network – to answer this question.
News Tofacitinib Through the Eyes of Patients: Rapid Response After Treatment Initiation
How does tofacitinib fare in the treatment of ulcerative colitis in real clinical practice from the patients' perspective? This was addressed in a recent study published in the journal Inflammatory Bowel Diseases.
News ESC 2022: Can Modern Treatment of Acute Heart Failure Improve (Re)hospitalization Prevention?
Heart failure (HF) and the possibilities of its therapy were one of the frequently discussed topics at this year's annual congress of the European Society of Cardiology (ESC 2022), which took place at the end of August in Barcelona. The potential of current approaches in reducing the risk of hospitalization or rehospitalization due to HF was also discussed. In summary, we present the insights from a symposium focused directly on this issue.
News Prokinetics in the Treatment of Diabetic Gastroparesis
One of the common complications of diabetes mellitus is a motility disorder of the gastrointestinal tract, which can affect any part of the digestive tube, and therefore has various forms. Among these therapeutically challenging conditions is diabetic gastroparesis, which involves impaired stomach emptying.
News Recommended and Not Recommended Physical Activity for Individuals with Hemophilia
Physical activity is now considered a fundamental prerequisite for maintaining the health of individuals with hemophilia. The World Federation of Hemophilia (WFH) also recommends it to improve fitness and neuromuscular health. Numerous studies have shown that physical activity can help enhance the effectiveness of hemophilia treatment and prevent bleeding episodes. In older individuals, including those with hemophilia, a lack of physical activity increases the risk of developing diabetes, hypertension, dyslipidemia, obesity, and osteoporosis, along with subsequent fractures and complications associated with hemophilia.
News Venetoclax in the Treatment of CLL: Open Doors for the Longest Possible Maintenance of Remission Without Active Therapy
William G. Wierda from MD Anderson Cancer Center in Houston, USA, and Francesco P. Tambaro from Azienda Ospedaliera di Rilievo Nazionale Santobono-Pausilipon in Naples, Italy, evaluate in their report for the journal Blood from April 2020 the practical aspects and benefits of using venetoclax in the first-line treatment of chronic lymphocytic leukemia (CLL), as well as in cases of relapsing/refractory forms of the disease.
News Effects of Telmisartan on Vascular Endothelial Functions, Inflammation Parameters, and Insulin Resistance in Patients with CHD and DM
Patients with coronary heart disease (CHD) and diabetes mellitus (DM) often have dysfunctional vascular endothelium, increased inflammatory markers, and insulin resistance. The study presented below investigated the effects of telmisartan on these parameters associated with disease progression and worse prognosis.
News Antiviral and Anti-inflammatory Effects of Alpha-1-Antitrypsin in the Treatment of COVID-19
Human alpha-1-antitrypsin (AAT) is a circulating blood glycoprotein that has been used for decades in the treatment of patients with AAT deficiency, lung damage, and emphysema, helping to prevent acute lung injury. Recently, it has been found that AAT also mitigates the course of COVID-19 disease by hindering the entry of the SARS-CoV-2 coronavirus into host cells. This dual antiviral and anti-inflammatory action makes AAT an excellent candidate for COVID-19 treatment.
News Immunomodulation and Romiplostim − What Does the Recently Published iROM Study Say?
Primary immune thrombocytopenia (ITP) is caused by an immunity disorder, involving not only the production of antibodies but also changes in cytokine levels, predominance of Th1 lymphocytes over Th2, increase in Th17 cells, and conversely a decrease in T-regulatory lymphocytes (Tregs). One treatment option is the use of thrombopoietin receptor agonists (TPO-RA), which primarily increase platelet production. Recently, attention has also been focused on their potential immunomodulatory effects and protolerogenic effect associated with Tregs activation, which was the subject of the Swiss iROM study.
News ESC 2022: What Do the Latest Real-World Data Say About the Use of DOACs in Atrial Fibrillation?
Why are real-world data so important? What new insights can they provide about established medications, such as direct oral anticoagulants (DOACs), in the treatment of patients with atrial fibrillation (AF)? What makes the GLORIA-AF registry unique, and what insights have been published from it this year? These topics were also discussed at the ESC 2022 Congress.
News Alpha-1 Antitrypsin Deficiency and Lung Disease in Patients with Primary Immunodeficiencies
Alpha-1 antitrypsin deficiency (AATD) plays a significant role in the pathogenesis of pulmonary emphysema, chronic obstructive pulmonary disease (COPD), and bronchiectasis. However, its deficiency may also play a role in other lung diseases.
News Pharmacokinetics and Safety Profile of Bilastine in Patients Aged 6–11 Years – Findings from Post-hoc Analysis of Studies
The second-generation antihistamine bilastine is approved in Europe for the treatment of allergic rhinoconjunctivitis and urticaria in children over 6 years old. Post-hoc analyses of two clinical studies focused on its safety profile and pharmacokinetics in the pediatric population.
News Emicizumab Changes the Lifestyle of Patients with Hemophilia A
At the World Federation of Hemophilia (WFH) meeting, data were presented regarding the impact of emicizumab on the lifestyle of people with hemophilia A.
News Does Emicizumab Change Routine Clinical Practice?
With the increasing number of patients with hemophilia A being treated with emicizumab, the question arises whether its use in any way changes established clinical practice. A team of American authors sought answers based on a survey conducted among the treating physicians of these patients. The findings were presented at the 13th Annual EAHAD Congress, which took place at the beginning of February in The Hague, Netherlands.
News Transition of Hemophilia A Patients with a History of Coagulation Factor Inhibitor to Emicizumab
During the World Federation of Hemophilia (WFH) conference, held virtually in June 2020, interesting results were presented for patients with Hemophilia A who had a history of FVIII inhibitor and are now using Emicizumab.
News Maintenance treatment with oral olaparib in women with BRCA1/2 mutation and relapsed ovarian cancer
In a phase III study published in the journal Lancet Oncology, data on the effectiveness of olaparib in patients with ovarian cancer and BRCA1/2 mutation were evaluated. The poly(ADP-ribose) polymerase (PARP) inhibitor olaparib had previously demonstrated effectiveness in a phase II study in patients with prior sensitivity to platinum-based treatments.
News Factors Predicting Longer Survival in Patients with Metastatic Colorectal Cancer Treated with Trifluridine/Tipiracil
A recently published non-interventional analysis evaluated overall survival (OS) and progression-free survival (PFS) in patients with metastatic colorectal cancer (mCRC) with favorable prognostic factors before initiating treatment with trifluridine/tipiracil compared to patients with unfavorable factors. It also identified which specific prognostic factors are favorable in terms of therapy effectiveness.
News Long-term Benefit of Luspatercept Therapy – Fresh Data from the MEDALIST Study
The goal of therapy for low-risk myelodysplastic syndrome (MDS) is to compensate for anemia, improve or maintain quality of life, and prolong the time to progression to higher-risk MDS (HR-MDS) or acute myeloid leukemia (AML). To manage anemia, we can resort to transfusion therapy or administer epoetins, lenalidomide, or luspatercept, the first representative of a class of drugs that support erythrocyte maturation. Last year's data from the follow-up of patients enrolled in the MEDALIST study pertain specifically to the latter.
News Treatment with Dupilumab in Severe Corticosteroid-Dependent Bronchial Asthma – A Case Study
We present the case of a 36-year-old woman with severe corticosteroid-dependent asthma with numerous comorbidities and complications due to long-term systemic corticosteroid therapy. Significant improvements in quality of life, asthma control, regression of skin changes in atopic dermatitis, and reduction in methylprednisolone consumption for this patient were only achieved after the initiation of biological treatment. Dupilumab, a monoclonal antibody against the α subunit of the receptor for interleukins IL-4 and IL-13, which is approved for the treatment of severe refractory eosinophilic bronchial asthma, atopic dermatitis, and chronic rhinosinusitis with nasal polyposis, was indicated in her treatment.
News Comparison of Cardiovascular Effects of Sitagliptin and Empagliflozin
Cardiovascular (CV) diseases remain the leading cause of death among patients with type 2 diabetes (T2D). Reducing the incidence of macrovascular CV events in diabetics requires more than just glycemic control alongside all other present CV risk factors. New antidiabetic drugs represent a very promising group of medications with a favorable safety profile, aiding in reducing the risk of CV complications.
News Impact of Adequate Protein Intake on Morbidity and Mortality in Critically Ill Patients
The following text provides a summary of findings from clinical studies in the field of nutritional therapy for critically ill patients and its impact on protein metabolism and patient outcomes.
News Ixekizumab is a Safe Option for Long-Term Treatment of Inflammatory Diseases
Psoriasis, psoriatic arthritis (PsA), and axial spondyloarthritis (SpA) are chronic inflammatory diseases that often require long-term treatment. The current pharmacotherapy of these diseases includes conventional synthetic disease-modifying antirheumatic drugs (DMARDs) and targeted biological therapies that inhibit the effects of tumor necrosis factor (TNF) or interleukins IL-23 and IL-17. An analysis published in early 2020 in the journal Rheumatology focused on the safety of long-term inhibition of IL-17A using ixekizumab.
News Romiplostim brings benefit also to patients with ITP lasting less than 1 year
What is the role of second-line therapy, in this case romiplostim, in the management of adult ITP patients who have not yet reached the chronic phase of the disease?
News Neutropenia with Thrombocytopenia after Alemtuzumab? − Case Report
Early neutropenia with thrombocytopenia is not a common side effect of alemtuzumab. However, the patient in the following case report by Italian colleagues was affected. What was the outcome?
News Prim. Pavel Jindra: Biosimilars are an accessible and effective treatment modality in hematooncology
“Based on our experience so far, biosimilars represent an effective and safe alternative to original molecules. We are not afraid to use them anywhere in approved indications, and we are not afraid of switching either. Biosimilars are a significant step towards greater accessibility of hematooncological treatment for a wide group of patients,” states the head of the Hematology-Oncology Department of FN Plzeň, MUDr. Pavel Jindra, Ph.D., in our current interview.